The interferon type i signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis

Annals of the Rheumatic Diseases

Volumn 75, Issue 8, 2016, Pages 1567-1573

  Brkic, Zana ^a   Van Bon, Lenny ^b,c   Cossu, Marta ^c,d   Van Helden Meeuwsen, Cornelia G ^a   Vonk, Madelon C ^c   Knaapen, Hanneke ^c   Van Den Berg, Wim ^c   Dalm, Virgil A ^a   Van Daele, Paul L ^a   Severino, Adriana ^d   Maria, Naomi I ^a   Guillen, Samara ^a   Dik, Willem A ^a   Beretta, Lorenzo ^d   Versnel, Marjan A ^a   Radstake, Timothy ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Autoimmune Diseases; Cytokines; Inflammation; Systemic Sclerosis

Indexed keywords

B CELL ACTIVATING FACTOR; MESSENGER RNA; PROCOLLAGEN; TYPE III PROCOLLAGEN N TERMINAL PROPEPTIDE; UNCLASSIFIED DRUG; INTERFERON; PEPTIDE FRAGMENT; PROCOLLAGEN TYPE III-N-TERMINAL PEPTIDE; TNFSF13B PROTEIN, HUMAN; TRANSCRIPTOME;

ADULT; ARTICLE; BAFF GENE; BLOOD SAMPLING; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTEMIC SCLEROSIS; AGED; BIOSYNTHESIS; BLOOD; CASE CONTROL STUDY; FIBROSIS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MONOCYTE; PATHOLOGY; SKIN;

ADULT; AGED; B-CELL ACTIVATING FACTOR; CASE-CONTROL STUDIES; FEMALE; FIBROSIS; GENE EXPRESSION REGULATION; HUMANS; INTERFERON TYPE I; MALE; MIDDLE AGED; MONOCYTES; PEPTIDE FRAGMENTS; PROCOLLAGEN; RNA, MESSENGER; SCLERODERMA, SYSTEMIC; SKIN; TRANSCRIPTOME;

EID: 84941702596     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-207392     Document Type: Article

References (33)

1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009;360:1989-2003.
2. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573-6.
3. Koenig M, Joyal F, Fritzler MJ, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynauds phenomenon to systemic sclerosis: A twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 2008;58:3902-12.
4. Vigone B, Santaniello A, Marchini M, et al Et al. Role of class II human leucocyte antigens in the progression from early to definite systemic sclerosis. Rheumatology (Oxford) 2015;54:707-11.
5. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: An American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 2013;72:1747-55.
6. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
7. Dieude P, Guedj M, Wipff J, et al. STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis. Arthritis Rheum 2009;60:2472-9.
8. Gourh P, Agarwal SK, Divecha D, et al. Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: evidence of possible gene-gene interaction and alterations in Th1/Th2 cytokines. Arthritis Rheum 2009;60:3794-806.
9. Ito I, Kawaguchi Y, Kawasaki A, et al. Association of a functional polymorphism in the IRF5 region with systemic sclerosis in a Japanese population. Arthritis Rheum 2009;60:1845-50.
10. Rueda B, Broen J, Simeon C, et al. The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype. Hum Mol Genet 2009;18:2071-7.
11. Tan FK, Zhou X, Mayes MD, et al. Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford) 2006;45:694-702.
12. York MR, Nagai T, Mangini AJ, et al. A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. Arthritis Rheum 2007;56:1010-20.
13. Duan H, Fleming J, Pritchard DK, et al. Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. Arthritis Rheum 2008;58:1465-74.
14. Farina G, Lafyatis D, Lemaire R, et al. A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2010;62:580-8.
15. van Bon L, Affandi AJ, Broen J, et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med 2013;370:433-43.
16. Leadbetter EA, Rifkin IR, Hohlbaum AM, et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002;416:603-7.
17. Ronnblom L, Eloranta ML. The interferon signature in autoimmune diseases. Curr Opin Rheumatol 2013;25:248-53.
18. Brkic Z, Maria NI, van Helden-Meeuwsen CG, et al. Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogrens syndrome and association with disease activity and BAFF gene expression. Ann Rheum Dis 2013;72:728-35.
19. Matsushita T, Hasegawa M, Yanaba K, et al. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 2006;54:192-201.
20. Knijff EM, Breunis MN, van Geest MC, et al. A relative resistance of T cells to dexamethasone in bipolar disorder. Bipolar Disord 2006;8:740-50.
21. Lyons PA, Koukoulaki M, Hatton A, et al. Microarray analysis of human leucocyte subsets: The advantages of positive selection and rapid purification. BMC Genomics 2007;8:64.
22. Staal FJ, Weerkamp F, Baert MR, et al. Wnt target genes identified by DNA microarrays in immature CD34+ thymocytes regulate proliferation and cell adhesion. J Immunol 2004;172:1099-108.
23. Beillard E, Pallisgaard N, van der Velden VH, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using real-Time quantitative reverse-Transcriptase polymerase chain reaction (RQ-PCR)-A Europe against cancer program. Leukemia 2003;17:2474-86.
24. Kirou KA, Lee C, George S, et al. Coordinate overexpression of interferon-Alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum 2004;50:3958-67.
25. Higgs BW, Liu Z, White B, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis 2011;70:2029-36.
26. Agarwal SK, Wu M, Livingston CK, et al. Toll-like receptor 3 upregulation by type I interferon in healthy and scleroderma dermal fibroblasts. Arthritis Res Ther 2011;13:R3.
27. Wutte N, Kovacs G, Berghold A, et al. CXCL13 and B-cell activating factor as putative biomarkers in systemic sclerosis. Br J Dermatol 2013;169:723-5.
28. Garcia-Romo GS, Caielli S, Vega B, et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med 2011;3:73ra20.
29. Groom J, Kalled SL, Cutler AH, et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogrens syndrome. J Clin Invest 2002;109:59-68.
30. Jacob N, Guo S, Mathian A, et al. B Cell and BAFF dependence of IFN-Alpha-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice. J Immunol 186:4984-93.
31. Kim D, Peck A, Santer D, et al. Induction of interferon-Alpha by scleroderma sera containing autoantibodies to topoisomerase I: Association of higher interferon-Alpha activity with lung fibrosis. Arthritis Rheum 2008;58:2163-73.
32. Eloranta ML, Franck-Larsson K, Lovgren T, et al. Type I interferon system activation and association with disease manifestations in systemic sclerosis. Ann Rheum Dis 2010;69:1396-402.
33. Liu X, Mayes MD, Tan FK, et al. Correlation of interferon-inducible chemokine plasma levels with disease severity in systemic sclerosis. Arthritis Rheum 2013;65:226-35.